Use of liposomes, emulsions, or inclusion complexes may potentiate in-vivo effects of SnET2

Abstract

The majority of second generation sensitizers being proposed as possible alternatives to hematoporphyrin derivative, in photodynamic therapy, are hydrophobic in nature. Consequently, specific carrier systems have to be developed for in vivo administration. As an attempt to understand the interactions of these delivery systems in vivo, plasma binding properties of the sensitizer SnET2 complexed with liposomes, emulsions or cyclodextrins have been studied. Additional studies have investigated the effect of the carrier system on the cytotoxicity of SnET2 on transplantable tumors. Preliminary data suggest that tumor response may be mediated by the choice of carrier system. Further studies appear to be necessary before the optimum thug/carrier system complex can be defined.